About Iovance Biotherapeutics, Inc.
https://www.iovance.comIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
CEO
Frederick G. Vogt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-09-26 | Reverse | 1:100 |
| 2010-05-26 | Forward | 23999:1000 |
ETFs Holding This Stock
Summary
Showing Top 3 of 122
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
Truist Securities
Buy
Mizuho
Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
MHR FUND MANAGEMENT LLC
Shares:28.97M
Value:$68.94M
BLACKROCK, INC.
Shares:25.96M
Value:$61.78M
VANGUARD GROUP INC
Shares:24.06M
Value:$57.26M
Summary
Showing Top 3 of 312
About Iovance Biotherapeutics, Inc.
https://www.iovance.comIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $67.45M ▲ | $160.95M ▲ | $-91.25M ▲ | -135.28% ▲ | $-0.25 ▲ | $-84.65M ▲ |
| Q2-2025 | $59.95M ▲ | $117.06M ▼ | $-111.66M ▲ | -186.25% ▲ | $-0.33 ▲ | $-101.84M ▲ |
| Q1-2025 | $49.32M ▼ | $120.8M ▲ | $-116.16M ▼ | -235.51% ▼ | $-0.36 ▼ | $-106.94M ▼ |
| Q4-2024 | $73.69M ▲ | $114.73M ▲ | $-78.56M ▲ | -106.6% ▲ | $-0.26 ▲ | $-74.89M ▲ |
| Q3-2024 | $58.55M | $107.8M | $-83.54M | -142.67% | $-0.28 | $-77.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $300.8M ▼ | $904.95M ▼ | $202.66M ▼ | $702.29M ▲ |
| Q2-2025 | $301.18M ▼ | $907.44M ▼ | $208.95M ▲ | $698.49M ▼ |
| Q1-2025 | $359.71M ▲ | $966.74M ▲ | $198.88M ▼ | $767.87M ▲ |
| Q4-2024 | $323.78M ▼ | $910.43M ▼ | $200.02M ▼ | $710.4M ▼ |
| Q3-2024 | $397.49M | $991.12M | $217.66M | $773.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-91.25M ▲ | $-78.7M ▼ | $17.01M ▲ | $88.06M ▲ | $25.66M ▲ | $-89.55M ▼ |
| Q2-2025 | $-111.66M ▲ | $-67.45M ▲ | $13.84M ▼ | $13.23M ▼ | $-39.64M ▼ | $-74.91M ▲ |
| Q1-2025 | $-116.16M ▼ | $-103.69M ▼ | $15.87M ▼ | $143.31M ▲ | $56M ▲ | $-109.91M ▼ |
| Q4-2024 | $-78.56M ▲ | $-73.3M ▼ | $23.68M ▲ | $2.31M ▼ | $-48.49M ▲ | $-77.46M ▼ |
| Q3-2024 | $-83.54M | $-58.97M | $-48.8M | $41.95M | $-64.57M | $-61.26M |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $100.00M ▲ | $50.00M ▼ | $60.00M ▲ | $70.00M ▲ |
CEO
Frederick G. Vogt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-09-26 | Reverse | 1:100 |
| 2010-05-26 | Forward | 23999:1000 |
ETFs Holding This Stock
Summary
Showing Top 3 of 122
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
Truist Securities
Buy
Mizuho
Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
MHR FUND MANAGEMENT LLC
Shares:28.97M
Value:$68.94M
BLACKROCK, INC.
Shares:25.96M
Value:$61.78M
VANGUARD GROUP INC
Shares:24.06M
Value:$57.26M
Summary
Showing Top 3 of 312